

Applicant : Jyh-Lyh Juang et al.  
Serial No. : 10/050,665  
Filed : January 16, 2002  
Page : 3

Attorney's Docket No.: 13217-002001

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and amend sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket no. 13217-002001.

Respectfully submitted,

Date: September 10, 2002

*Leda Liu, Reg. No. 50,635*  
for Y. Rocky Tsao  
Reg. No. 34,053

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Applicant : Jyh-Lyh Juang et al.  
Serial No. : 10/050,665  
Filed : January 16, 2002  
Page : 4

Attorney [REDACTED] Socket No.: 13217-002001

**"Version With Markings to Show Changes Made"**

In the specification:

Paragraph beginning at page 12, line 17, has been amended as follows:

In this example, an EGFP gene was positioned under the control of a polyhedrin promoter. This promoter is active in Sf21 cells but silent in *Drosophila* S2 cells. EGFP was used as a reporter gene to estimate transfection efficiencies and relative protein expression levels. The plasmid pBacEGFP was constructed by subcloning a EGFP PCR product into pBacPAK8 (Clontech) at *Bam HI* and *Pac I* sites and the EGFP PCR product was amplified from pEGFP-1 (Clontech) with specific primers. The primers used for PCR were as follows:

5EGFP/*Bam HI*:

5'CAGGATCCGCCACCATGGTGAGCAAGGGCG (SEQ ID NO:1) ; and

3EGFP/*Pac I*:

3'TCGTTAATTAAATTACTTGTACAGCTCGTCCATG (SEQ ID NO:[2] 3).